ADMET considerations for restless leg syndrome drug treatments

Author： de Biase Stefano   Merlino Giovanni   Lorenzut Simone   Valente Mariarosaria   Gigli Gian Luigi  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.8, Iss.10, 2012-10, pp. : 1247-1261

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Zonisamide: Restless leg syndrome: case report

By  

Reactions Weekly, Vol. 1, Iss. 1164, 2007-01 ,pp. : 27-27

Adis International

Access to resources Recommend Favorite

Metabolic and toxicological considerations for sepsis drug treatments

By Campbell Sarah C   Spigarelli Michael G   Courter Joshua   Sherwin Catherine MT  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 1, 2013-01 ,pp. : 79-89

Informa Healthcare

Access to resources Recommend Favorite

ADMET considerations for phosphodiesterase-5 inhibitors

By Rezvanfar Mohammad Amin   Rahimi Hamid Reza   Abdollahi Mohammad  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 10, 2012-10 ,pp. : 1231-1245

Informa Healthcare

Access to resources Recommend Favorite

Pramipexole Responsive Neck Numbness: The Therapeutic Role of Dopamine Agonists in the Spinal Cord Indicating to a Common Spinal Pathophysiology with Restless Leg Syndrome (RLS)?

By  

Current Clinical Pharmacology, Vol. 11, Iss. 3, 2016-09 ,pp. : 221-222

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacotherapy for restless legs syndrome

By Ferini-Strambi Luigi   Marelli Sara  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 8, 2014-06 ,pp. : 1127-1138

Informa Healthcare

Access to resources Recommend Favorite